Rockeby has seen a tremendous upsurge in activities and possibilities, which not only translated into additional opportunities but also increased sales.
The Company’s goals are to fi nalize negotiations with our European partners, commence sales in the fi rst quarter of 2007 for CanDia5® and other products in the infectious disease range which we have promised to source and market to our partners there.
Additionally, Rockeby believes that the demand for veterinary Infl uenza A tests will continue to
soar and we expect to be able to book several of the tenders we are involved in. Concurrently,
Rockeby’s management team will be busy with driving forward the joint venture in China,
where we expect to have some concrete results to present to our shareholders by the end of
this calendar year.
The board and management of Rockeby would like to invite you to continue to follow the Company’s successful transformation and participate in this exciting new phase of Rockeby.
Dr. Tan Sze Wee
Managing Director & CEO
Rockeby biomed Limited
